Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
14.7 million in net revenue for the third quarter 2021 Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. today issued its financial results for the third quarter ended September 30, 2021. ...
Source: investingnews.com